DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
What Are the U.S. Market Access and Prescribing Hurdles for the Oral Therapies Looming Large on the Horizon for Atherothrombotic Diseases? | Physician & Payer Forum | US | 2015
A Survey of Non-interventional Cardiologists and Managed Care Organization Pharmacy and Medical Directors Atherosclerosis refers to the thickening of arterial walls due to deposition of plaque;…
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (First Line) | Decision Base | US | 2015
What Key Attributes Do Oncologists and Payers Believe Will Differentiate Emerging Therapies? The first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) market is becoming…
Prostate Cancer (First-Line [Chemotherapy-Naive] Metastatic Castrate-Resistant) | DecisionBase | US | 2015
What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Increasingly Competitive Market? In recent years, several new, high-priced…
Systemic Lupus Eryhtematosus (What Market Access Levers and Barriers Will Emerging Biologics for SLE Face in Europe?) | Physician & Payer Forum | EU5 | 2014
In 2011, GlaxoSmithKline’s Benlysta became the first biological treatment ever approved for systemic lupus erythematosus (SLE) and the first drug approved for SLE in more than 50 years. However,…
Squamous Cell Carcinoma of the Head and Neck | Niche and Rare Pharmacor | G7 | 2014
Squamous cell carcinoma of the head and neck (SCCHN) is one of the six most frequently diagnosed malignancies worldwide. Second/third primary tumors are the main threats to long-term survival once…
